The State Drug Administration's notice on 19 batches of medicines does not meet the requirements

The State Drug Administration's notice on 19 batches of medicines does not meet the requirements

(No. 32, 2022)

After inspection by 10 pharmaceutical inspection institutions such as Hubei Pharmaceutical Supervision and Inspection and Research Institute, 19 batches of drugs such as acetylcysteine ​​injections produced by Ruiyang Pharmaceutical Co., Ltd. were not in line with regulations. The relevant situation is notified as follows:

I. The inspection by the Liaoning Provincial Pharmaceutical Inspection and Inspection Institute, marked that a batch of 1 batch produced by Shanghai Diran City Pharmaceutical Co., Ltd. relies on erythromycin particles and does not meet the regulations, and does not meet the requirements of the specified project as the content measurement.

After inspection by the Hubei Provincial Institute of Drug Administration, the two batches of acetylcysteine ​​injection produced by Ruiyang Pharmaceutical Co., Ltd. did not meet the regulations and did not meet the specified projects as hydrogen sulfide.

The two batches of Longze Xiong Bile Capsules produced by Tonghua Zhongsheng Pharmaceutical Co., Ltd. did not meet the requirements and did not meet the requirements of the specified projects and collapse time limit.

After inspection by the Food and Drug Inspection and Research Institute of Shandong Province, a batch of ginseng Jianpi Pills produced by Tianjin Sino -Singapore Pharmaceutical Group Co., Ltd. Daren Pharmaceutical Factory did not meet the regulations, and did not meet the requirements of the specified projects as the difference.

After inspection by the Food and Drug Inspection and Research Institute of Tibet Autonomous Region, a batch of fifteen -flavored Black Pharmaceutical Pills produced by the Tibetan Pharmaceutical Factory of Tibet did not meet the regulations, and it did not meet the requirements of the specified projects as heavy differences and microorganisms.

After inspection by the Food and Drug Inspection Institute of Henan Province, the two batches of Ai leaves produced by Harbin Songshantang Pharmaceutical Co., Ltd. and Sichuan Jiuwei Pavilion Traditional Chinese Medicine Crimination Co., Ltd. do not meet the requirements, and the projects are not in line with regulations.

After inspection by the Sichuan Pharmaceutical Inspection and Research Institute (Sichuan Medical Device Inspection Center), a batch of Sichuan Achyranthes bulls produced by Hubei Minatai Pharmaceutical Co., Ltd. did not meet the regulations and did not meet the requirements of the specified projects as traits.

After inspection by the China Food and Drug Inspection Research Institute, the three batches of chrysanthemums produced by Jiangsu Donglian Pharmaceutical Co., Ltd., Anhui Wan Sheng Traditional Chinese Medicine Drinking Co., Ltd., and Hunan Songling Traditional Chinese Medicine Drinking Co., Ltd. did not meet the requirements, and did not meet the regulations. The projects are banned from pesticide residues.

After inspection by the Gansu Provincial Academy of Pharmaceutical Inspection and Research, it is marked as the 4 batches of Qiancao produced by Guangzhou Weida Traditional Chinese Medicine Drinking Co., Ltd., Sichuan Yuancao Traditional Chinese Medicine Drinking Co., Ltd., and Sichuan Yunbatang Pharmaceutical Co., Ltd. The project includes traits, micro -identification, and immersion; 1 batch of Qiancao (Qiancao charcoal) produced by Sichuan Xinkang Traditional Chinese Medicine Drinking Piection Co., Ltd. does not meet the requirements and does not meet the specified projects as traits.

After inspection by the Institute of Food and Drug Inspection of Anhui Province, a batch of peach kernels (燀 燀 燀) produced by Zhangshu City Qingren Traditional Chinese Medicine Drinking Co., Ltd. did not meet the regulations and did not meet the requirements of the regulations as the base value.

2. For the above -mentioned do not meet the prescribed drugs, the drug supervision and management department has required relevant enterprises and units to take risk control measures such as suspension of sales, recall, and recall, and conduct investigations and rectification on reasons for not compliance.

3. The State Drug Administration requires relevant provincial drug supervision and management departments to organize investigations on suspected illegal acts existing above -mentioned enterprises and units in accordance with the "Drug Administration Law of the People's Republic of China", and publicize the results of the investigation and punishment in accordance with regulations.

announce.

Attachment: 1.19 batches do not meet the specified drug list

2. Do not meet the specified projects of the project

State Drug Administration

July 6, 2022

appendix

Recognize the QR code to view:

1.19 batches do not meet the specified drug list

2. Do not meet the specified projects of the project

- END -